← Back to All US Stocks

Absci Corp (ABSI) Stock Fundamental Analysis & AI Rating 2026

ABSI Nasdaq Services-Commercial Physical & Biological Research CIK: 0001672688
Updated This Month • Analysis: Mar 19, 2026 • SEC Data: 2025-09-30
Combined AI Rating
STRONG SELL
90% Confidence
STRONG AGREEMENT
STRONG SELL
92% Conf
STRONG SELL
89% Conf

📊 ABSI Key Takeaways

Revenue: $2.2M
Net Margin: -3,982.4%
Free Cash Flow: $-65.0M
Current Ratio: 5.89x
Debt/Equity: 0.02x
EPS: $-0.65
AI Rating: STRONG SELL with 92% confidence
Absci Corp (ABSI) receives a STRONG SELL rating with 90% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $2.2M, net profit margin of -3,982.4%, and return on equity (ROE) of -40.7%, Absci Corp demonstrates mixed fundamentals in the Healthcare sector. Below is our complete ABSI stock analysis for 2026.

Is Absci Corp (ABSI) a Good Investment?

Claude

Absci is a pre-revenue research services company with severe operational losses and negative cash flows that are unsustainable. Despite holding $9.5M in cash with minimal debt, the company is burning capital at an alarming rate (~$63.7M operating cash burn annually) with only $2.1M in revenue, indicating a fundamental business model problem. At current cash burn rates, the company has less than 2 months of cash runway without immediate operational changes or external funding.

ChatGPT

Absci's fundamentals are very weak: revenue is minimal and flat at $2.15M while operating and net losses remain extremely large relative to the business size, producing deeply negative margins and cash flow. The balance sheet is not highly levered and current liquidity ratios look strong, but the combination of only $9.48M in cash against substantial operating cash burn suggests limited runway and a high likelihood that growth will require external funding. Until revenue scales meaningfully and losses narrow materially, the growth quality appears poor.

Why Buy Absci Corp Stock? ABSI Key Strengths

Claude
  • + Strong balance sheet with minimal debt (0.02x debt/equity ratio)
  • + Adequate current ratio (5.89x) indicating short-term liquidity at current run rate
  • + Total assets of $245M provide some liquidation value backing
ChatGPT
  • + Low financial leverage with debt/equity of 0.02x and limited long-term debt
  • + Strong reported current and quick ratios, indicating near-term balance sheet flexibility
  • + Large equity base relative to liabilities provides some balance sheet support

ABSI Stock Risks: Absci Corp Investment Risks

Claude
  • ! Catastrophic cash burn of $63.7M operating cash flow against only $2.1M revenue indicates business model failure
  • ! Negative operating margin of -4152% demonstrates severe profitability challenges
  • ! Critical cash runway of approximately 6-7 weeks at current burn rate without revenue growth or cost reduction
  • ! Free cash flow of -$65M annually is unsustainable and requires immediate financing or restructuring
  • ! Zero revenue growth (flat YoY) combined with massive operating losses indicates no path to profitability
  • ! 15 Form 4 insider filings in 90 days may signal management uncertainty or distress
ChatGPT
  • ! Revenue is very small and showed no year-over-year growth, indicating weak commercial traction
  • ! Extreme negative profitability with operating margin of -4152.4% and net margin of -3982.4%
  • ! Operating cash burn is severe relative to cash on hand, increasing financing and dilution risk

Key Metrics to Watch

Claude
  • * Monthly cash burn rate and cash runway remaining
  • * Revenue growth trajectory and contract backlog
  • * Operating expense reduction initiatives and path to cash flow breakeven
  • * Capital raising activities and dilution to shareholders
  • * Customer acquisition and contract values
ChatGPT
  • * Quarterly revenue growth and evidence of commercial scaling
  • * Operating cash burn relative to cash balance and resulting funding runway

Absci Corp (ABSI) Financial Metrics & Key Ratios

Revenue
$2.2M
Net Income
$-85.6M
EPS (Diluted)
$-0.65
Free Cash Flow
$-65.0M
Total Assets
$245.0M
Cash Position
$9.5M

💡 AI Analyst Insight

Strong liquidity with a 5.89x current ratio provides a solid financial cushion.

ABSI Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin -4,152.4%
Net Margin -3,982.4%
ROE -40.7%
ROA -34.9%
FCF Margin -3,021.1%

ABSI vs Healthcare Sector: How Absci Corp Compares

How Absci Corp compares to Healthcare sector averages

Net Margin
ABSI -3,982.4%
vs
Sector Avg 12.0%
ABSI Sector
ROE
ABSI -40.7%
vs
Sector Avg 15.0%
ABSI Sector
Current Ratio
ABSI 5.9x
vs
Sector Avg 2.0x
ABSI Sector
Debt/Equity
ABSI 0.0x
vs
Sector Avg 0.6x
ABSI Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Absci Corp Stock Overvalued? ABSI Valuation Analysis 2026

Based on fundamental analysis, Absci Corp has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
-40.7%
Sector avg: 15%
Net Profit Margin
-3,982.4%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.02x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Absci Corp Balance Sheet: ABSI Debt, Cash & Liquidity

Current Ratio
5.89x
Quick Ratio
5.89x
Debt/Equity
0.02x
Debt/Assets
14.1%
Interest Coverage
-507.25x
Long-term Debt
$4.0M

ABSI Revenue & Earnings Growth: 5-Year Financial Trend

ABSI 5-year financial data: Year 2021: Revenue $4.1M, Net Income -$14.4M, EPS $-3.19. Year 2022: Revenue $4.5M, Net Income -$101.0M, EPS $-2.08. Year 2023: Revenue $5.7M, Net Income -$104.9M, EPS $-1.15. Year 2024: Revenue $5.7M, Net Income -$110.6M, EPS $-1.20. Year 2025: Revenue $4.5M, Net Income -$103.1M, EPS $-0.94.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Absci Corp's revenue has grown significantly by 10% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.94 indicates the company is currently unprofitable.

ABSI Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-3,021.1%
Free cash flow / Revenue

ABSI Quarterly Earnings & Performance

Quarterly financial performance data for Absci Corp including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $378.0K -$22.0M $-0.20
Q2 2025 $593.0K -$22.0M $-0.22
Q1 2025 $898.0K -$22.0M $-0.21
Q3 2024 $744.0K -$22.0M $-0.24
Q2 2024 $1.3M -$22.0M $-0.22
Q1 2024 $898.0K -$22.0M $-0.22
Q3 2023 $744.0K -$22.0M $-0.24
Q2 2023 $636.0K -$23.4M $-0.32

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

Absci Corp Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$63.7M
Cash generated from operations
Capital Expenditures
$1.2M
Investment in assets
Dividends
None
No dividend program

ABSI SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Absci Corp (CIK: 0001672688)

📋 Recent SEC Filings

Date Form Document Action
Mar 24, 2026 10-K absi-20251231.htm View →
Mar 24, 2026 8-K absc-20260324.htm View →
Mar 16, 2026 4 xslF345X05/wk-form4_1773692239.xml View →
Mar 6, 2026 8-K absc-20260303.htm View →
Mar 5, 2026 4 xslF345X05/wk-form4_1772755011.xml View →

Frequently Asked Questions about ABSI

What is the AI rating for ABSI?

Absci Corp (ABSI) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.

What are ABSI's key strengths?

Claude: Strong balance sheet with minimal debt (0.02x debt/equity ratio). Adequate current ratio (5.89x) indicating short-term liquidity at current run rate. ChatGPT: Low financial leverage with debt/equity of 0.02x and limited long-term debt. Strong reported current and quick ratios, indicating near-term balance sheet flexibility.

What are the risks of investing in ABSI?

Claude: Catastrophic cash burn of $63.7M operating cash flow against only $2.1M revenue indicates business model failure. Negative operating margin of -4152% demonstrates severe profitability challenges. ChatGPT: Revenue is very small and showed no year-over-year growth, indicating weak commercial traction. Extreme negative profitability with operating margin of -4152.4% and net margin of -3982.4%.

What is ABSI's revenue and growth?

Absci Corp reported revenue of $2.2M.

Does ABSI pay dividends?

Absci Corp does not currently pay dividends.

Where can I find ABSI SEC filings?

Official SEC filings for Absci Corp (CIK: 0001672688) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is ABSI's EPS?

Absci Corp has a diluted EPS of $-0.65.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is ABSI a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, Absci Corp has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is ABSI stock overvalued or undervalued?

Valuation metrics for ABSI: ROE of -40.7% (sector avg: 15%), net margin of -3,982.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy ABSI stock in 2026?

Our dual AI analysis gives Absci Corp a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is ABSI's free cash flow?

Absci Corp's operating cash flow is $-63.7M, with capital expenditures of $1.2M. FCF margin is -3,021.1%.

How does ABSI compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin -3,982.4% (avg: 12%), ROE -40.7% (avg: 15%), current ratio 5.89 (avg: 2).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 19, 2026 | Data as of: 2025-09-30 | Powered by Claude AI